Consensus-based recommendation for surveillance of peripheral neuropathy

This page is part of the PanCare follow-up recommendations for surveillance of late effects. Click here, for more information on these recommendations.

Who is at risk for and should be aware of peripheral neuropathy?

CAYA cancer survivors treated with

  • vinca-alkaloids
  • cisplatin or carboplatin

What should be done if abnormalities are identified?

  • Refer to the appropriate HCP

  • Consider medication for painful neuropathy